Azitra, Inc. — Form 8-K

Azitra announced protocol amendments to its Phase 1/2 clinical trial (NCT06830863) of ATR04-484 expanding patient eligibility beyond EGFR inhibitor-associated rash to include patients with rash from KRAS inhibitors, MEK inhibitors, and neurofibromatosis type 1 patients on MEK inhibitors. The amendments also shorten antibiotic and steroid washout periods. No financial figures, share counts, or counterparty relationships disclosed; the expansion addresses an estimated 85,000 annual KRAS/MEK inhibitor patients plus 100,000 NF1 patients in the US, broadening the addressable market from 220,000 EGFRi patients to potentially 405,000+ patients.